MWNA
KYMR icon

Marshall Wace North America’s Kymera Therapeutics KYMR Stock Holding History

Marshall Wace North America’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7,269
Closed -$235K – 1447
2020
Q3 		$235K Buy
+7,269
New +$222K ﹤0.01% 1109

Other funds holding KYMR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DIC
Deer IX & Co Larchmont, New York $971M AUM 24.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace North America's KYMR Position: Q4 2020 in Review

Marshall Wace North America sold out of Kymera Therapeutics (KYMR) in Q4 2020, closing a stake of 7,269 shares — an estimated $235K sold.

Marshall Wace North America first reported a position in KYMR in Q3 2020 and held it in 1 quarter. The position peaked at $235K in Q3 2020. 75 funds tracked by Wall St. Rank hold KYMR as of Q4 2020.

  • Marshall Wace North America reported no remaining Kymera Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 7,269 Kymera Therapeutics shares in Q4 2020, an estimated $235K.
  • Marshall Wace North America first reported a position in Kymera Therapeutics in Q3 2020 and held it in 1 quarter.
  • Marshall Wace North America's Kymera Therapeutics position peaked at $235K in Q3 2020.
  • 75 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.